We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00365001
First Posted: August 16, 2006
Last Update Posted: June 11, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hoffmann-La Roche
August 15, 2006
August 16, 2006
June 11, 2010
Not Provided
Not Provided
Pharmacokinetic parameters for simvastatin and metabolite, and methotrexate and metabolite. [ Time Frame: Days 1, 15 and 43 ]
PK parameters for simvastatin, and metabolite, and methotrexate and metabolite (AUC last, AUCinf, Cmax, Tmax, T1/2, CL/F).
Complete list of historical versions of study NCT00365001 on ClinicalTrials.gov Archive Site
  • Pharmacokinetic parameters for tocilizumab. [ Time Frame: Days 11, 22, 29 and 36. ]
  • CRP, IL-6, sIL-6R changes [ Time Frame: Throughout study ]
  • AEs, laboratory parameters. [ Time Frame: Throughout study ]
Pharmacokinetics: PK parameters for tocilizumab. Pharmacodynamics: CRP, IL-6, sIL-6R changes. Safety: AEs, laboratory parameters.
Not Provided
Not Provided
 
A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
A Randomized, Open-label Study to Assess the Pharmacokinetics of Simvastatin and Methotrexate in Combination With Tocilizumab in Patients With Rheumatoid Arthritis.
This 2 arm study will investigate the pharmacokinetics of simvastatin and methotrexate in combination with tocilizumab to assess any potential drug interactions. Patients will be randomized to receive either tocilizumab (10mg/kg iv infusion on day 8) + methotrexate (10-25mg po /week) or tocilizumab + methotrexate + simvastatin (40mg po on days 1, 15 and 43). Blood samples will be taken for analysis at intervals up to day 44. The anticipated time on study treatment is <3 months, and the target sample size is <100 individuals.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Rheumatoid Arthritis
  • Drug: tocilizumab [RoActemra/Actemra]
    10mg/kg iv on day 8
  • Drug: Methotrexate
    10-25mg po/week
  • Drug: Simvastatin
    40mg po on days 1, 15 and 43
  • Experimental: 1
    Interventions:
    • Drug: tocilizumab [RoActemra/Actemra]
    • Drug: Methotrexate
    • Drug: Simvastatin
  • Active Comparator: 2
    Interventions:
    • Drug: tocilizumab [RoActemra/Actemra]
    • Drug: Methotrexate
Schmitt C, Kuhn B, Zhang X, Kivitz A, Grange S. Tocilizumab has no clinically relevant effects on methotrexate pharmacokinetics in patients with rheumatoid arthritis. Int J Clin Pharmacol Ther. 2012 Mar;50(3):218-23.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
23
April 2008
Not Provided

Inclusion Criteria:

  • adult patients, 18-75 years of age;
  • rheumatoid arthritis for >=6 months;
  • methotrexate for >=12 weeks prior to day 1 (stable at 10-25mg/week for 8 weeks).

Exclusion Criteria:

  • history of, or current inflammatory joint disease or rheumatic autoimmune disease other than RA;
  • concurrent treatment with any DMARD other than methotrexate;
  • prior treatment with tocilizumab.
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
New Zealand,   United States
 
 
NCT00365001
WP18663
Not Provided
Not Provided
Not Provided
Clinical Trials, Study Director, Hoffmann-La Roche
Hoffmann-La Roche
Not Provided
Study Director: Clinical Trials Hoffmann-La Roche
Hoffmann-La Roche
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP